Glucocorticoid osteoporosis

Journal of Intensive Care Medicine

Volumn 14, Issue 5, 1999, Pages 231-242

  Reid, Ian R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; FLUORIDE; GLUCOCORTICOID; SEX HORMONE; VITAMIN D;

BONE ATROPHY; BONE DENSITY; BONE MASS; DRUG INDUCED DISEASE; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; OSTEOBLAST; OSTEOPOROSIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW;

EID: 0032823174     PISSN: 08850666     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1489.1999.00231.x     Document Type: Review

References (119)

1. Weinstein RS, Jilka RL, Parfitt AM, et al. Inhibition of osteo blastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids-potential mechanisms of their deleterious effects on bone. J Clin Invest 1998;102: 274-282
2. Dempster DW. Bone histomorphometry in glucocorticoidinduced osteoporosis. J Bone Miner Res 1989;4:137-141
3. Gallagher JA, Beresford JN, MacDonald BR, et al. Hormone target cell interactions in human bone. In: Christiansen C, ed. Osteoporosis. Copenhagen: Osteopress ApS, 1984
4. Dietrich JW, Canalis EM, Maina DM, et al. Effects of glucocorticoids on fetal rat bone collagen synthesis in vitro. Endocrinology 1979;104:715-721
5. Boden SD, Hair G, Titus L, et al. Glucocorticoid-induced differentiation of fetal rat calvarial osteoblasts is mediated by bone morphogenetic protein-6. Endocrinology 1997; 138:2820-2828
6. Pandipati S, Driscoll JE, Franceschi RT. Glucocorticoid stimulation of Na + -dependent ascorbic acid transport in osteoblast-like cells. J Cell Physiol 1998;176:85-91
7. Chang DJ, Ji C, Kim KK, et al. Reduction in transforming growth factor beta receptor I expression and transcription factor cbfa1 on bone cells by glucocorticoid. J Biol Chem 1998;273:4892-4896
8. Mahonen A, Jukkola A, Risteli J, et al. Type I procollagen synthesis is regulated by steroids and related hormones in human osteosarcoma cells. J Cell Biochem 1998;68:151-163
9. Rogatsky I, Trowbridge JM, Garabedian MJ. Glucocorticoid receptor-mediated cell cycle arrest is achieved through distinct cell-specific transcriptional regulatory mechanisms. Mol Cell Biol 1997;17:3181-3193
10. Hulley PA, Gordon F, Hough FS. Inhibition of mitogen-activated protein kinase activity and proliferation of an early osteoblast cell line (mba 15.4) by dexamethasone -role of protein phosphatases. Endocrinology 1998;139: 2423-2431
11. Chevalley T, Strong DD, Mohan S, et al. Evidence for a role for insulin-like growth factor binding proteins in glucocorticoid inhibition of normal human osteoblast-like cell proliferation. Eur J Endocrinol 1996;134:591-601
12. Gabbitas B, Pash JM, Delany AM, et al. Cortisol inhibits the synthesis of insulin-like growth factor-binding protein-5 in bone cell cultures by transcriptional mechanisms. J Biol Chem 1996;271:9033-9038
13. Okazaki R, Riggs BL, Conover CA. Glucocorticoid regulation of insulin-like growth factor-binding protein expression in normal human osteoblast-like cells. Endocrinology 1994;134:126-132
14. Gabbitas B, Canalis E. Cortisol enhances the transcription of insulin-like growth factor-binding protein-6 in cultured osteoblasts. Endocrinology 1996;137:1687-1692
15. Reid IR, Katz J, Ibbertson HK, et al. The effects of hydrocortisone, parathyroid hormone and the bisphosphonate APD on bone resorption in neonatal mouse calvaria. Calcif Tissue Int 1986;38:38-43
16. Godschalk MF, Downs RW. Effect of short-term glucocorticoids on serum osteocalcin in healthy young men. J Bone Miner Res 1988;3:113-115
17. Shuto T, Kukita T, Hirata M, et al. Dexamethasone stimulates osteoclast-like cell formation by inhibiting granulocyte-macrophage colony-stimulating factor production in mouse bone marrow cultures. Endocrinology 1994;134: 1121-1126
18. Kaji H, Sugimoto T, Kanatani M, et al. Dexamethasone stimulates osteoclast-like cell formation by directly acting on hemopoietic blast cells and enhances osteoclast-like cell formation stimulated by parathyroid hormone and prostaglandin e-2. J Bone Miner Res 1997;12:734-741
19. Tobias J, Chambers TJ. Glucocorticoids impair bone resorptive activity and viability of osteoclasts disaggregated from neonatal rat long bones. Endocrinology 1989;125: 1290-1295
20. Dempster DW, Moonga BS, Stein LS, et al. Glucocorticoids inhibit bone resorption by isolated rat osteoclasts by enhancing apoptosis. J Endocrinol 1997;154:397-406
21. Caputo CB, Meadows D, Raisz LG. Failure of estrogens and androgens to inhibit bone resorption in tissue culture. Endocrinology 1976;98:1065-1068
22. Lowe C, Gray DH, Reid IR. Serum blocks the osteolytic effect of cortisol in neonatal mouse calvaria. Calcif Tissue Int 1992;50:189-192
23. Gronowicz G, McCarthy MB, Raisz LG. Glucocorticoids stimulate resorption in fetal rat parietal bones in vitro. J Bone Miner Res 1990;5:1223-1230
24. Swolineide D, Ohlsson C. Effects of cortisol on the expression of interleukin-6 and interleukin-1-beta in human osteoblast-like cells. J Endocrinol 1998;156:107-114
25. Malaval L, Gupta AK, Liu F, et al. LIF, but not IL-6, regulates osteoprogenitor differentiation in rat calvaria cell cultures: modulation by dexamethasone. J Bone Miner Res 1998;13: 175-184
26. Rubin J, Biskobing DM, Jadhav L, et al. Dexamethasone promotes expression of membrane-bound macrophage colony-stimulating factor in murine osteoblast-like cells. Endocrinology 1998;139:1006-1012
27. Chavassieux P, Buffet A, Vergnaud P, et al. Short-term effects of corticosteroids on trabecular bone remodeling in old ewes. Bone 1997;20:451-455
28. Welten DC, Kemper HCG, Post GB, et al. Weight-bearing activity during youth is a more important factor for peak bone mass than calcium intake. J Bone Miner Res 1994;9: 1089-1096
29. Gray RE, Doherty SM, Galloway J, et al. A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders. Arthritis Rheum 1991;34: 287-295
30. Reid IR, Ibbertson HK. Evidence for decreased tubular reabsorption of calcium in glucorticoid-treated asthmatics. Horm Res 1987;27:200-204
31. Cosman F, Nieves J, Herbert J, et al. High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J Bone Miner Res 1994;9:1097-1105
32. Braun JJ, Juttman JR, Visser TJ, et al. Short-term effect of prednisone on serum 1,25-hydroxy-vitamin D in normal individuals an in hyper- and hypoparathyroidism. Clin Endocrinol 1982;17:21-28
33. Fucik RF, Kukreja SC, Hargis GK, et al. Effect of glucocorticoids on function of the parathyroid glands in man. J Clin Endocrinol Metab 1975;40:152-185
34. Tsai KS, Lin JC, Chen CK, et al. Effect of exercise and exogenous glucocorticoid on serum level of intact parathyroid hormone. Int J Sports Med 1997;18:583-587
35. Pearce G, Tabensky DA, Delmas PD, et al. Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab 1998; 83:801-806
36. Au WY. Cortisol stimulation of parathyroid hormone secretion by rat parathyroid glands in organ culture. Science 1976;193:1015-1017
37. Sugimoto T, Brown AJ, Ritter C, et al. Combined effects of dexamethasone and 1,25-dihydroxyvitamin D3 on parathyroid hormone secretion in cultured bovine parathyroid cells. Endocrinology 1989;125:638-641
38. Butler RC, Davie MW, Worsfold M, et al. Bone mineral content in patients with rheumatoid arthritis: relationship to low-dose steroid therapy. Br J Rheumatol 1991;30:86-90
39. Peraldi MN, Rondeau E, Jousset V, et al. Dexamethasone increases preproparathyroid hormone messenger RNA in human hyperplastic parathyroid cells in vitro. Eur J Clin Invest 1990;20:392-397
40. Bikle DD, Halloran B, Fong L, et al. Elevated 1,25-dihydroxyvitamin-D levels in patients with chronic obstructive pulmonary disease treated with prednisone. J Clin Endocrinol Metab 1993;76:456-461
41. Hattersley AT, Meeran K, Burrin J, et al. The effect of long- and short-term corticosteroids on plasma calcitonin and parathyroid hormone levels. Calcif Tissue Int 1994;54: 198-202
42. Mahgoub A, Hirsch PF, Munson PL. Calcium-lowering action of glucocorticoids in adrenalectomized-parathyroidectomized rats - specificity and relative potency of natural and synthetic glucocorticoids. Endocrine 1997;6:279-283
43. Chen TL, Feldman D. Glucocorticoid receptors and actions in subpopulations of cultured rat bone cells. J Clin Invest 1979;63:750-758
44. Hahn TJ, Halstead LR. Cortisol enhancement of PTH-stimulated cyclic AMP accumulation in cultured fetal rat long bone rudiments. Calcif Tissue Int 1979;29:173-175
45. Titus L, Rubin JE, Lorang MT, et al. Glucocorticoids and 1,25-dihydroxyvitamin D3 regulate parathyroid hormone stimulation of adenosine 3′,5′-monophosphate-dependent protein kinase in rat osteosarcoma cells. Endocrinology 1988;123:1526-1534
46. Zajac JD, Livesey SA, Michelangeli VP, et al. Glucocorticoid treatment facilitates cyclic adenosine 3′,5′-monophosphate-dependent protein kinase response in parathyroid hormone-responsive osteogenic sarcoma cells. Endocrinology 1986;118:2059-2064
47. Mitchell J, Bansal A. Dexamethasone increases g-alpha(q-11) expression and hormone-stimulated phospholipase C activity in umr-106-01 cells. Am J Physiol Endocrinol Metab 1997;36:E528-E535
48. Smals AG, Kloppenborg PW, Benraad TJ. Plasma testosterone profiles in Cushing's syndrome. J Clin Endocrinol Metab 1977;45:240-245
49. Reid IR, France JT, Pybus J, et al. Low plasma testosterone levels in glucocorticoid-treated male asthmatics. BMJ 1985; 291:574
50. Morrison D, Capewell S, Reynolds SP, et al. Testosterone levels during systemic and inhaled corticosteroid therapy. Respir Med 1994;88:659-663
51. Fitzgerald RC, Skingle SJ, Crisp AJ. Testosterone concentrations in men on chronic glucocorticosteroid therapy. J R Coll Physicians Lond 1997;31:168-170
52. MacAdams MR, White RH, Cipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986;104:648-651
53. Reid IR, Veale AG, France JT. Glucocorticoid osteoporosis. J Asthma 1994;31:7-18
54. Rivier C, Vale W. Effects of long-term administration of corticotropin-releasing factor on the pituitary-adrenal and pituitary-gonadal axis in the male rat. J Clin Invest 1985; 75:689-694
55. Mann DR, Jackson GC, Blank MS. Influence of adrenocorticotropin and adrenalectomy on gonadotropin secretion in immature rats. Neuroendocrinology 1982;34:20-26
56. Ringstom SJ, Schwartz NZ. Cortisol suppresses the LH, but not the FSH, response to gonadotropin-releasing hormone after orchidectomy. Endocrinology 1985;116:472-474
57. Sakakura M, Takebe K, Nakagawa S. Inhibition of luteinizing hormone secretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects. J Clin Endocrinol Metab 1975;40:774-779
58. Saez JM, Morera AM, Haour F, et al. Effects of in vivo administration of dexamethasone, corticotropin and human chorionic gonadotropin on steroidogenesis and protein and DNA synthesis of testicular interstitial cells in prepubertal rats. Endocrinology 1977;101:1256-1263
59. Doerr P, Pirke KM. Cortisol-induced suppression of plasma testosterone in normal adult males. J Clin Endocrinol Metab 1976;43:622-629
60. Schaison G, Durand F, Mowszowicz I. Effect of glucocorticoids on plasma testosterone in men. Acta Endocrinol (Copenhagen) 1978;89:126-131
61. Irvine WJ, Toft AD, Wilson KS. The effect of synthetic corticotropin analogues on adrenocortical, anterior pituitary and testicular function. J Clin Endocrinol Metab 1974; 39:522-529
62. Turner HE, Wass JA. Gonadal function in men with chronic illness. Clin Endocrinol (Oxf) 1997;47:379-403
63. LoCascio V, Bonucci E, Imbimbo B, et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner 1990;8:39-51
64. Laan RF, van Riel PL, van de Putte LB, et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 1993;119:963-968
65. Saito JK, Davis JW, Wasnich RD, et al. Users of low-dose glucocorticoids have increased bone loss rates: a longitudinal study. Calcif Tissue Int 1995;57:115-119
66. Reid IR, Heap SW. Determinants of vertebral mineral density in patients receiving chronic glucocorticoid therapy. Arch Intern Med 1990;150:2545-2548
67. Hall GM, Spector TD, Griffin AJ, et al. The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. Arthritis Rheum 1993;36:1510-1516
68. Mateo L, Nolla JM, Rozadilla A, et al. Bone mineral density in patients with temporal arteritis and polymyalgia rheumatica. J Rheumatol 1993;20:1369-1373
69. Thompson JM, Modin GW, Arnaud CD, et al. Not all postmenopausal women on chronic steroid and estrogen treatment are osteoporotic: predictors of bone mineral density. Calcif Tissue Int 1997;61:377-381
70. Huizenga NA, Koper JW, De Lange P, et al. A polymorphism in the glucocorticoid receptor gene may be associated with an increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab 1998;83:144-151
71. Rizzato G, Montemurro L. Reversibility of exogenous corticosteroid-induced bone loss. Eur Respir J 1993;6:116-119
72. Lane SJ, Vaja S, Swaminathan R, et al. Effects of prednisolone on bone turnover in patients with corticosteroid resistant asthma. Clin Exp Allergy 1996;26:1197-1201
73. Reid IR, Evans MC, Wattie DJ, et al. Bone mineral density of the proximal femur and lumbar spine in glucocorticoidtreated asthmatic patients. Osteoporos Int 1992;2:103-105
74. Reid IR, Evans MC, Stapleton J. Lateral spine densitometry is a more sensitive indicator of glucocorticoid-induced bone loss. J Bone Miner Res 1992;7:1221-1225
75. Lufkin EG, Wahner HW, Bergstralh EJ. Reversibility of steroid-induced osteoporosis. Am J Med 1988;85:887-888
76. Hermus AR, Smals AG, Swinkels LM, et al. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome. J Clin Endocrinol Metab 1995;80: 2859-2865
77. Manning PJ, Evans MC, Reid IR. Normal bone mineral density following cure of Cushing's syndrome. Clin Endocrinol 1992;36:229-234
78. Gluck OS, Murphy WA, Hahn TJ, et al. Bone loss in adults receiving alternate day glucocorticoid therapy. Arthritis Rheum 1981;24:892-898
79. Ruegsegger P, Medici TC, Anliker M. Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol 1983;25: 615-620
80. Doull I, Freezer N, Holgate S. Osteocalcin, growth, and inhaled corticosteroids - a prospective study. Arch Dis Child 1996;74:497-501
81. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997;337: 8-14
82. Pauwels RA, Yernault JC, Demedts MG, et al. Safety and efficacy of fluticasone and bedomethasone in moderate to severe asthma. Am J Respir Crit Care Med 1998;157: 827-832
83. Efthimiou J, Barnes PJ. Effects of inhaled corticosteroids on bones and growth. Eur Respir J 1998;11:1167-1177
84. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983;309: 265-268
85. Luengo M, Picado C, Del Rio L, et al. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax 1991;46:803-806
86. Michel BA, Bloch DA, Fries JF. Predictors of fractures in early rheumatoid arthritis. J Rheumatol 1991;18:804-808
87. Laan RF, van Riel PL, van Erning LJ, et al. Vertebral osteoporosis in rheumatoid arthritis patients: effect of low dose prednisone therapy. Br J Rheumatol 1992;31:91-96
88. Spector TD, Hall GM, McCloskey EV, et al. Risk of vertebral fracture in women with rheumatoid arthritis. BMJ 1993; 306:558
89. Lems WF, Jahangier ZN, Jacobs JW, et al. Vertebral fractures in patients with rheumatoid arthritis treated with corticosteroids. Clin Exp Rheumatol 1995;13:293-297
90. McEvoy CE, Ensrud KE, Bender E, et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:704-709
91. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995;54:49-52
92. Michel BA, Bloch DA, Wolfe F, et al. Fractures in rheumatoid arthritis - an evaluation of associated risk factors. J Rheumatol 1993;20:1666-1669
93. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-387
94. Rodino MA, Shane E. Osteoporosis after organ transplantation. Am J Med 1998;104:459-469
95. Klein GL. Metabolic bone disease of total parenteral nutrition. In: Favus MJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. Philadelphia: Lippincott-Raven, 1996
96. Finkelstein JS, Cleary RL, Butler JP, et al. A comparison of lateral versus anterior-posterior spine dual energy x-ray absorptiometry for the diagnosis of osteopenia. J Clin Endocrinol Metab 1994;78:724-730
97. Blanckaert F, Cortet B, Coquerelle P, et al. Contribution of calcaneal ultrasonic assessment to the evaluation of postmenopausal and glucocorticoid-induced osteoporosis. Rev Rhum 1997;64:305-313
98. Koskudla B, Pluskiewicz W. Quantitative ultrasound of the heel and serum and urinary cortisol values in assessment of long-term corticotherapy side effects in female bronchial asthma patients. Ultrasound Med Biol 1997;23:1325-1330
99. Hall GM, Spector TD, Delmas PD. Markers of bone metabolism in postmenopausal women with rheumatoid arthritis - effects of corticosteroids and hormone replacement therapy. Arthritis Rheum 1995;38:902-906
100. Reeve J, Loftus J, Hesp R, et al. Biochemical prediction of changes in spinal bone mass in juvenile chronic (or rheumatoid) arthritis treated with glucocorticoids. J Rheumatol 1993;20:1189-1195
101. Shane E, Rivas M, McMahon DJ, et al. Bone loss and turnover after cardiac transplantation. J Clin Endocrinol Metab 1997;82:1497-1506
102. Sambrook PN, Kelly PJ, Fontana D, et al. Mechanisms of rapid bone loss following cardiac transplantation. Osteoporos Int 1994;4:273-276
103. Reid IR, King AR, Alexander CJ, et al. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1988;1:143-146
104. Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993:328:1747-1752
105. Reid IR, Ibbertson HK. Calcium supplements in the prevention of steroid-induced osteoporosis. Am J Clin Nutr 1986; 44:287-290
106. Nilsen KH, Jayson MI, Dixon AS. Macrocrystalline calcium hydroxyapatite compound in corticosteroid-treated rheumatoid patients: a controlled study. Br Med J 1978;2:1124
107. Buckley LM, Leib ES, Cartularo KS, et al. Calcium and vitamin D-3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis - a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;125:961-968
108. Adachi JD, Bensen WG, Bianchi F, et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis - a 3 year followup. J Rheumatol 1996;23:995-1000
109. Hahn TJ, Halstead LR, Teitelbaum SL, et al. Altered mineral metabolism in glucocorticoid-induced osteopenia. J Clin Invest 1979;64:655-665
110. Di Munno O, Beghe F, Favini P, et al. Prevention of glucocorticoid-induced osteopenia: effect of oral 25-hydroxyvitamin D and calcium. Clin Rheumatol 1989;8:202-207
111. Gallacher SJ, Fenner JA, Anderson K, et al. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study. Thorax 1992;47:932-936
112. Saag KG. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998; 339:292-299
113. Boutsen Y, Jamart J, Esselinckx W, et al. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate - a randomized trial. Calcif Tissue Int 1997;61:266-271
114. Grynpas MD, Kasra M, Renlund R, et al. The effect of pamidronate in a new model of immobilization in the dog. Bone 1995;17:S225-S232
115. Reid IR, Wattie DJ, Evans MC, et al. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996;156: 1173-1177
116. Grey AB, Cundy TF, Reid IR. Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in post-menopausal osteoporosis. Clin Endocrinol 1994;40:671-677
117. Rizzoli R, Chevalley T, Slosman DO, et al. Sodium monofluorophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis. Osteoporos Int 1995;5:39-46
118. Lems WF, Jacobs WG, Bijlsma JW, et al. Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis. Osteoporos Int 1997;7:575-582
119. Adachi JD, Bensen WG, Bell MJ, et al. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br J Rheumatol 1997;36:255-259